期刊文献+

肺纤方对博莱霉素致肺纤维化大鼠一般情况和肺组织形态学的影响 被引量:1

Effect of Formula for Lung Fibrosis on general conditions and pulmonary histomorphology of rats with pulmonary fibrosis induced by Bleocamicina
原文传递
导出
摘要 目的观察肺纤方对博来霉素造模的肺纤维化大鼠肺组织病理形态发展的影响。方法 144只健康Wistar大鼠随机分成对照组,模型组,阳性组,肺纤方高、中、低剂量组,每组各24只,按Szapiel等法建立模型,次日ig给药,肺纤方高、中、低剂量(3.2、1.6、0.8g/kg)组均为10mL/kg药液ig给药,阳性对照组用醋酸泼尼松混悬液(6mg/kg)ig给药,对照组与模型组ig等量生理盐水,1次/d,给药周期21d。分别在造模7、14、21d后取材,前后期各随机杀检10只,中期杀检4只对照验证。结果与模型对照组相比,肺纤方高剂量组在改善大鼠外观、体质量、肺系数、肺脏病理组织形态学等方面效果较好(P<0.05或P<0.01),中剂量组几乎与阳性对照组作用相当,而阳性对照组先期作用好于治疗组,但中后期时肺纤方高剂量组的疗效明显好于阳性组,说明肺纤方抗大鼠肺纤维化病变的长期疗效优于阳性组。结论肺纤方是防治肺纤维化的一种有效方剂,对博莱霉素致大鼠肺损伤具有一定的保护作用,对肺纤维化具有干预作用,且呈现一定的量效关系。 Objective To observe the curative effect of Formula for Lung Fibrosis on pulmonary fibrosis of rat model induced by Bleocamicina.. Methods Healthy Wistar rats (144) were randomly divided into six groups: control group, model group, prednisone acetate (PA, positive control) group, high-, mid-, and low-dose Formula for Lung Fibrosis groups, and there were 24 rats in each group. The rat model was established by Szapiel's method. On the next day, the three treatment groups were ig administrated with high-, mid-, and low-dose Formula for Lung Fibrosis (3.2, 1.6, and 0.8 g/kg, 10 mL/kg body weight); The rats in PA group were ig administrated with PA (6 mg/kg); And the rats of control group and model group were ig administrated with physiological saline at the same dose, once daily for 21 d. After 7, 14, and 21 days of model establishment, 10 rats, 4 rats, and 10 rats were randomly sacrificed, respectively, and the materials were drawn, observed, recorded, and analyzed. Results Compared with the model group, high-dose Formula for Lung Fibrosis showed the significant difference on improving rat appearance, body weight, lung coefficient, and pathological histomorphology (P 〈 0.05 or 0.01). Mid-dose Formula for Lung Fibrosis had the same effect as PA group almost, and PA group was better than treatment group in beginning stage but worse in intermediate and later stages. This directed that high-dose Formula for Lung Fibrosis had better effect than PA group markedly, and the long-term effect of Formula for Lung Fibrosis was superior to PA. Conclusion Formula for Lung Fibrosis is an effective formula in treating and preventing pulmonary fibrosis. It could intervene in the injury of rats caused by Bleocamicina, and show a dose-effect relationship.
机构地区 山西省中医院
出处 《现代药物与临床》 CAS 2012年第5期451-456,共6页 Drugs & Clinic
基金 山西省科技攻关项目(20090311055-2)
关键词 肺纤方 博来霉素 肺纤维化 病理形态 Formula for Lung Fibrosis Bleocamicina pulmonary fibrosis pathological morphology
  • 相关文献

参考文献5

二级参考文献20

  • 1戴令娟,侯杰,蔡后荣,王伟,孟繁青,倪瑾.肺纤维化动物模型肺组织形态定量分析[J].南京铁道医学院学报,1996,15(1):24-27. 被引量:13
  • 2谢东浩,蔡宝昌,安益强,李霞,贾晓斌.柴胡皂苷类化学成分及药理作用研究进展[J].南京中医药大学学报,2007,23(1):63-65. 被引量:114
  • 3郭红.雾化吸入氨基胍对大鼠肺纤维化的影响及其机制的研究.河北医科大学学报,2007,:1-2.
  • 4IzbiekiG, SegelMJ, ChristensenTG, et al. Time course of bleomycin-inducedlung fibrosis. Int JExP Path ,2002 ;83 : 111
  • 5PaulG, Reinhart, Laiavb YL, et al. An iodarone induced Pulmonary fibrosis in Fischer 344 rats. Toxicology, 1996 ; 110:95
  • 6SelmanM, King TE Ji, Pardo A. ldio. Pathic Pulmonary fibrosis:Prevailing and evolving hypotheses about its Pathogeneais and imPlieatians for therapy. Ann Intern Meal,2001 ;134(2) :136 - 151
  • 7Collard HR, Ryu JH, Douglas WW, et al. Combined corticesteroid and CyeloPhosPhamide therapy does not alter survival in idiopathic pulmonary fibrosis. Chest ,2004,125 (6) :2169 - 2174
  • 8Luppi F, Cerri S, Beghe B, et al. Cortieosteroid and immunomodultory Agents in idiopathic Pulmonary fibrosis. Respiratory Medieine, 2004;9 (11) :1035 -1044
  • 9何燕,胡志峰,李平,肖诚,陈玉武,李克明,郭景珍,潘琳,熊佳鹏.柴胡皂苷d抗肝纤维化大鼠脂质过氧化作用的研究[J].中国中药杂志,2008,33(8):915-919. 被引量:72
  • 10裴旭,陈少贤.特发性肺纤维化的治疗进展[J].国际内科学杂志,2008,35(5):280-283. 被引量:4

共引文献34

同被引文献16

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部